IHMA Europe Sàrl, 1066 Epalinges, Switzerland.
International Health Management Associates, Schaumburg, IL 60173-3817, USA.
J Med Microbiol. 2014 Apr;63(Pt 4):556-561. doi: 10.1099/jmm.0.068981-0. Epub 2014 Jan 29.
A subset of Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates collected for the Study for Monitoring Antimicrobial Resistance Trends that were positive for the Clinical and Laboratory Standards Institute (CLSI) extended-spectrum β-lactamase (ESBL) phenotypic confirmatory test (n = 3245) or had an ertapenem MIC of ≥0.5 µg ml(-1) (n = 293), or both (n = 467), were analysed for ESBL genes. Most ESBL phenotype E. coli or K. pneumoniae possessed an ESBL gene (95.8 and 88.4 %, respectively), and this was 93.1 % if carbapenem-non-susceptible K. pneumoniae were removed. This rate was lower for P. mirabilis (73.4 %) and K. oxytoca (62.5 %). Virtually all ESBL-positive isolates (99.5 %) were cefotaxime non-susceptible [CLSI or European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints)]. Fewer isolates (82 %) were ceftazidime non-susceptible (CLSI breakpoints). In addition, 21.1 % of E. coli, 25 % of K. oxytoca and 78.7 % of P. mirabilis isolates were ceftazidime susceptible but ESBL positive. This suggests that CLSI breakpoints for ceftazidime are too high to detect ESBLs. The lower EUCAST breakpoints detected ESBLs in E. coli and K. oxytoca better, but 59.6 % of ESBL-positive isolates of P. mirabilis were ceftazidime susceptible. For isolates with ertapenem MICs ≥0.5 µg ml(-1), more accurate ESBL phenotype analysis was observed for E. coli and K. pneumoniae (sensitivity >95 % for both, specificity 94.4 and 54.1 %, respectively). If carbapenemase-positive K. pneumoniae were excluded, the specificity increased to 78 %. The positive predictive values for the ESBL phenotypic test with E. coli and K. pneumoniae were 97.6 and 81.8 %, respectively, and negative predictive values were 75.9 and 95.2 %, respectively. We therefore suggest that it would be prudent to confirm phenotypic ESBL-positive P. mirabilis, K. pneumoniae and K. oxytoca with molecular analysis.
对收集用于监测抗菌药物耐药趋势的研究中的 3245 株经临床和实验室标准协会(CLSI)扩展型β-内酰胺酶(ESBL)表型确证试验阳性或厄他培南 MIC≥0.5 µg/ml(293 株)或两者均阳性(467 株)的大肠埃希氏菌、产酸克雷伯菌、肺炎克雷伯菌和奇异变形杆菌分离株进行 ESBL 基因分析。大多数 ESBL 表型大肠埃希氏菌或肺炎克雷伯菌均具有 ESBL 基因(分别为 95.8%和 88.4%),如果去除耐碳青霉烯类肺炎克雷伯菌,则这一比例为 93.1%。奇异变形杆菌(73.4%)和产酸克雷伯菌(62.5%)的这一比例较低。几乎所有 ESBL 阳性分离株(99.5%)对头孢噻肟均不敏感[CLSI 或欧洲抗菌药物敏感性试验委员会(EUCAST)折点]。对头孢他啶不敏感的分离株较少(82%)(CLSI 折点)。此外,21.1%的大肠埃希氏菌、25%的产酸克雷伯菌和 78.7%的奇异变形杆菌分离株对头孢他啶敏感但 ESBL 阳性。这表明 CLSI 对头孢他啶的折点过高,无法检测 ESBL。较低的 EUCAST 折点对大肠埃希氏菌和产酸克雷伯菌的 ESBL 检测效果更好,但 59.6%的奇异变形杆菌 ESBL 阳性分离株对头孢他啶敏感。对于厄他培南 MIC≥0.5 µg/ml 的分离株,对大肠埃希氏菌和肺炎克雷伯菌的 ESBL 表型分析更为准确(敏感性均>95%,特异性分别为 94.4%和 54.1%)。如果去除耐碳青霉烯类肺炎克雷伯菌,则特异性增加至 78%。大肠埃希氏菌和肺炎克雷伯菌 ESBL 表型试验的阳性预测值分别为 97.6%和 81.8%,阴性预测值分别为 75.9%和 95.2%。因此,我们建议对表型 ESBL 阳性奇异变形杆菌、肺炎克雷伯菌和产酸克雷伯菌进行分子分析以确认是合理的。